This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (37)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

Steven Sevush, MD; Wenche Jy, PhD; Lawrence L. Horstman; Wei-Wei Mao; Luciano Kolodny, MD; Yeon S. Ahn, MD

Arch Neurol. 1998;55:530-536.

Background  In light of recent reports of diminished platelet serotonin concentration and increased plasma serotonin levels in patients with Alzheimer disease (AD), we hypothesized that a state of heightened platelet activation might be present in AD.

Objective  To compare baseline activation of unstimulated platelets in patients with AD with that in control subjects.

Patients and Methods  Flow cytometry was used to measure platelet activation in 91 patients with probable AD and 40 age-matched control subjects. Groups were compared for percentage of circulating platelet aggregates, expression of CD62p, formation of leukocyte-platelet complexes, and presence of circulating platelet microparticles, controlling for effects of demographic, clinical, physiological, and logistical factors.

Results  Multiple analysis of covariance on ranked data revealed a 39.5% increase in percentage of platelet aggregates (P=.0001), a 59.3% increase in expression of CD62p (P=.001), and a 53.3% increase in leukocyte-platelet complexes (P=.0001) in the group with AD but no differences in the number of platelet microparticles, overall platelet count, plasma fibrinogen level, or plasma platelet factor 3. Activation was weakly correlated with sex, but was independent of age, severity of disease, duration of disease, depression, agitation, and family history of dementia.

Conclusions  Platelets of patients with AD exhibit greater unstimulated activation than those of controls. Potential causes of such activation include possible stimulation of platelets by damaged cerebral endothelial cells or platelet activation induced by membrane abnormalities previously reported to be present in platelets of patients with AD. In light of recent evidence that platelets are the principal source of both amyloid precursor protein and -amyloid peptide in human blood, it is possible that AD platelet activation may reflect or even contribute to the pathogenesis of the disease.

From the Departments of Psychiatry and Neurology (Dr Sevush) and the William J. Harrington Sr Center for Blood Diseases, Department of Medicine (Drs Jy, Kolodny, and Ahn, and Messrs Horstman and Mao), University of Miami School of Medicine, Miami, Fla.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Activation of Human Platelets by Misfolded Proteins
Herczenik et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:1657-1665.
ABSTRACT | FULL TEXT  

Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia
van Oijen et al.
Stroke 2005;36:2637-2641.
ABSTRACT | FULL TEXT  

Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease
Padovani et al.
Arch Neurol 2002;59:71-75.
ABSTRACT | FULL TEXT  

Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD
Padovani et al.
Neurology 2001;57:2243-2248.
ABSTRACT | FULL TEXT  

Platelets and atrial fibrillation
Kamath et al.
Eur Heart J 2001;22:2233-2242.
 

Platelet activation: assessment and quantification
Kamath et al.
Eur Heart J 2001;22:1561-1571.
 

Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde
McGrath et al.
QJM 2001;94:485-490.
ABSTRACT | FULL TEXT